ImmunoPrecise Antibodies Ltd. (IPA)
USD 0.43
(-0.46%)
USD 0.43
(-0.46%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 26.06 Million CAD | 30.27% |
| 2022 | 20.01 Million CAD | 9.89% |
| 2021 | 18.2 Million CAD | 81.45% |
| 2020 | 10.03 Million CAD | -17.59% |
| 2019 | 12.17 Million CAD | 18.49% |
| 2018 | 10.27 Million CAD | -13.44% |
| 2017 | 11.87 Million CAD | 1318.6% |
| 2016 | 836.91 Thousand CAD | 77.26% |
| 2015 | 472.15 Thousand CAD | 85.42% |
| 2014 | 254.64 Thousand CAD | -16.1% |
| 2013 | 303.49 Thousand CAD | 14.26% |
| 2012 | 265.62 Thousand CAD | 24.65% |
| 2011 | 213.1 Thousand CAD | 93.36% |
| 2010 | 110.2 Thousand CAD | 12.6% |
| 2009 | 97.87 Thousand CAD | -35.12% |
| 2008 | 150.84 Thousand CAD | 302.67% |
| 2007 | 37.46 Thousand CAD | -90.94% |
| 2006 | 413.69 Thousand CAD | 198.43% |
| 2005 | 138.62 Thousand CAD | 193.83% |
| 2004 | 47.17 Thousand CAD | -5.49% |
| 2003 | 49.91 Thousand CAD | 69.03% |
| 2002 | 29.53 Thousand CAD | -84.27% |
| 2001 | 187.72 Thousand CAD | -79.07% |
| 2000 | 896.74 Thousand CAD | 8770.78% |
| 1999 | 10.1 Thousand CAD | -71.75% |
| 1998 | 35.78 Thousand CAD | -46.9% |
| 1997 | 67.38 Thousand CAD | -73.05% |
| 1996 | 250.03 Thousand CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 26.44 Million CAD | -31.52% |
| 2023 FY | 26.06 Million CAD | 30.27% |
| 2023 Q4 | 26.06 Million CAD | -9.71% |
| 2023 Q1 | 13.7 Million CAD | -31.52% |
| 2023 Q2 | 23.57 Million CAD | 72.05% |
| 2023 Q3 | 28.86 Million CAD | 22.45% |
| 2022 Q2 | 21.01 Million CAD | 53.34% |
| 2022 Q4 | 20.01 Million CAD | -6.31% |
| 2022 Q1 | 13.7 Million CAD | -24.75% |
| 2022 FY | 20.01 Million CAD | 9.89% |
| 2022 Q3 | 21.35 Million CAD | 1.64% |
| 2021 Q2 | 9.42 Million CAD | 4.77% |
| 2021 Q3 | 8.76 Million CAD | -7.09% |
| 2021 Q1 | 8.99 Million CAD | -10.32% |
| 2021 Q4 | 18.2 Million CAD | 107.87% |
| 2021 FY | 18.2 Million CAD | 81.45% |
| 2020 FY | 10.03 Million CAD | -17.59% |
| 2020 Q1 | 13.5 Million CAD | 10.9% |
| 2020 Q3 | 11.34 Million CAD | -10.17% |
| 2020 Q4 | 10.03 Million CAD | -11.51% |
| 2020 Q2 | 12.62 Million CAD | -6.52% |
| 2019 Q4 | 12.17 Million CAD | 9.6% |
| 2019 FY | 12.17 Million CAD | 18.49% |
| 2019 Q3 | 11.11 Million CAD | -5.56% |
| 2019 Q1 | 12.16 Million CAD | 18.37% |
| 2019 Q2 | 11.76 Million CAD | -3.28% |
| 2018 Q4 | 10.27 Million CAD | 13.14% |
| 2018 Q3 | 9.08 Million CAD | -12.69% |
| 2018 Q1 | 11.63 Million CAD | -1.99% |
| 2018 FY | 10.27 Million CAD | -13.44% |
| 2018 Q2 | 10.4 Million CAD | -10.59% |
| 2017 Q1 | 540.66 Thousand CAD | -35.4% |
| 2017 FY | 11.87 Million CAD | 1318.6% |
| 2017 Q4 | 11.87 Million CAD | 304.15% |
| 2017 Q3 | 2.93 Million CAD | 10.47% |
| 2017 Q2 | 2.65 Million CAD | 391.83% |
| 2016 Q1 | 241.1 Thousand CAD | -7.08% |
| 2016 Q4 | 836.91 Thousand CAD | 12.71% |
| 2016 Q2 | 241.33 Thousand CAD | 0.1% |
| 2016 Q3 | 742.54 Thousand CAD | 207.69% |
| 2016 FY | 836.91 Thousand CAD | 77.26% |
| 2015 Q4 | 259.45 Thousand CAD | 1.46% |
| 2015 Q2 | 239.69 Thousand CAD | 0.12% |
| 2015 Q1 | 239.39 Thousand CAD | -7.88% |
| 2015 FY | 472.15 Thousand CAD | 85.42% |
| 2015 Q3 | 255.72 Thousand CAD | 6.69% |
| 2014 Q2 | 266.21 Thousand CAD | -7.68% |
| 2014 Q3 | 254.64 Thousand CAD | -4.35% |
| 2014 Q4 | 259.86 Thousand CAD | 2.05% |
| 2014 FY | 254.64 Thousand CAD | -16.1% |
| 2014 Q1 | 288.35 Thousand CAD | 0.33% |
| 2013 Q3 | 303.49 Thousand CAD | 5.89% |
| 2013 Q2 | 286.62 Thousand CAD | -0.49% |
| 2013 Q1 | 288.04 Thousand CAD | 6.84% |
| 2013 Q4 | 287.4 Thousand CAD | -5.3% |
| 2013 FY | 303.49 Thousand CAD | 14.26% |
| 2012 FY | 265.62 Thousand CAD | 24.65% |
| 2012 Q4 | 269.6 Thousand CAD | 1.5% |
| 2012 Q3 | 265.62 Thousand CAD | 12.21% |
| 2012 Q2 | 236.71 Thousand CAD | 3.76% |
| 2012 Q1 | 228.14 Thousand CAD | -1.82% |
| 2011 Q4 | 232.37 Thousand CAD | 9.04% |
| 2011 Q2 | 184.26 Thousand CAD | 49.27% |
| 2011 Q1 | 123.44 Thousand CAD | 44.9% |
| 2011 Q3 | 213.1 Thousand CAD | 15.65% |
| 2011 FY | 213.1 Thousand CAD | 93.36% |
| 2010 Q4 | 85.19 Thousand CAD | -22.7% |
| 2010 Q2 | 184.27 Thousand CAD | 70.21% |
| 2010 Q1 | 108.26 Thousand CAD | 7.76% |
| 2010 FY | 110.2 Thousand CAD | 12.6% |
| 2010 Q3 | 110.2 Thousand CAD | -40.19% |
| 2009 Q4 | 100.47 Thousand CAD | 2.65% |
| 2009 Q2 | 57.57 Thousand CAD | 2.38% |
| 2009 Q3 | 97.87 Thousand CAD | 70.01% |
| 2009 FY | 97.87 Thousand CAD | -35.12% |
| 2009 Q1 | 56.23 Thousand CAD | -24.98% |
| 2008 Q1 | 76.72 Thousand CAD | 157.38% |
| 2008 Q2 | 375.9 Thousand CAD | 389.94% |
| 2008 Q3 | 150.84 Thousand CAD | -59.87% |
| 2008 FY | 150.84 Thousand CAD | 302.67% |
| 2008 Q4 | 74.94 Thousand CAD | -50.31% |
| 2007 Q2 | 28.65 Thousand CAD | -53.89% |
| 2007 Q1 | 62.13 Thousand CAD | -60.13% |
| 2007 FY | 37.46 Thousand CAD | -90.94% |
| 2007 Q4 | 29.81 Thousand CAD | -20.42% |
| 2007 Q3 | 37.46 Thousand CAD | 30.74% |
| 2006 Q4 | 155.85 Thousand CAD | -62.33% |
| 2006 FY | 413.69 Thousand CAD | 198.43% |
| 2006 Q1 | 50.53 Thousand CAD | 1.63% |
| 2006 Q3 | 413.69 Thousand CAD | -25.92% |
| 2006 Q2 | 558.42 Thousand CAD | 1005.13% |
| 2005 Q4 | 49.71 Thousand CAD | -64.13% |
| 2005 Q3 | 138.62 Thousand CAD | -79.06% |
| 2005 Q2 | 662.06 Thousand CAD | 75.25% |
| 2005 Q1 | 377.77 Thousand CAD | 991.91% |
| 2005 FY | 138.62 Thousand CAD | 193.83% |
| 2004 Q2 | 122.08 Thousand CAD | 5.73% |
| 2004 Q3 | 47.17 Thousand CAD | -61.36% |
| 2004 FY | 47.17 Thousand CAD | -5.49% |
| 2004 Q4 | 34.59 Thousand CAD | -26.66% |
| 2004 Q1 | 115.47 Thousand CAD | 282.26% |
| 2003 FY | 49.91 Thousand CAD | 69.03% |
| 2003 Q3 | 49.91 Thousand CAD | -62.96% |
| 2003 Q1 | 33.14 Thousand CAD | 106.85% |
| 2003 Q2 | 134.77 Thousand CAD | 306.67% |
| 2003 Q4 | 30.2 Thousand CAD | -39.49% |
| 2002 FY | 29.53 Thousand CAD | -84.27% |
| 2002 Q4 | 16.02 Thousand CAD | -45.75% |
| 2002 Q2 | 18.86 Thousand CAD | -39.34% |
| 2002 Q1 | 31.1 Thousand CAD | -87.56% |
| 2002 Q3 | 29.53 Thousand CAD | 56.56% |
| 2001 Q4 | 249.93 Thousand CAD | 33.14% |
| 2001 Q1 | 217.38 Thousand CAD | -73.37% |
| 2001 Q2 | 186.46 Thousand CAD | -14.23% |
| 2001 Q3 | 187.72 Thousand CAD | 0.68% |
| 2001 FY | 187.72 Thousand CAD | -79.07% |
| 2000 Q2 | 164.69 Thousand CAD | 149.29% |
| 2000 Q4 | 816.23 Thousand CAD | -8.98% |
| 2000 Q1 | 66.06 Thousand CAD | 317.69% |
| 2000 FY | 896.74 Thousand CAD | 8770.78% |
| 2000 Q3 | 896.74 Thousand CAD | 444.48% |
| 1999 FY | 10.1 Thousand CAD | -71.75% |
| 1999 Q4 | 15.81 Thousand CAD | 56.46% |
| 1999 Q3 | 10.1 Thousand CAD | 0.0% |
| 1998 Q3 | 35.78 Thousand CAD | 0.0% |
| 1998 FY | 35.78 Thousand CAD | -46.9% |
| 1997 FY | 67.38 Thousand CAD | -73.05% |
| 1997 Q3 | 67.38 Thousand CAD | 0.0% |
| 1996 FY | 250.03 Thousand CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Acurx Pharmaceuticals, Inc. | 3.04 Million USD | -756.78% |
| Adaptive Biotechnologies Corporation | 352.85 Million USD | 92.613% |
| IO Biotech, Inc. | 17.55 Million USD | -48.479% |
| VYNE Therapeutics Inc. | 8.95 Million USD | -191.251% |
| Organovo Holdings, Inc. | 2.74 Million USD | -848.581% |
| TNF Pharmaceuticals, Inc. | 5.08 Million USD | -412.26% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -6353.697% |
| Tonix Pharmaceuticals Holding Corp. | 48.93 Million USD | 46.728% |
| Aadi Bioscience, Inc. | 27.22 Million USD | 4.264% |
| Savara Inc. | 37.19 Million USD | 29.912% |
| Aerovate Therapeutics, Inc. | 17.96 Million USD | -45.123% |
| Rocket Pharmaceuticals, Inc. | 73.76 Million USD | 64.663% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | 25.898% |
| ZyVersa Therapeutics, Inc. | 11.03 Million USD | -136.121% |
| Soligenix, Inc. | 7.27 Million USD | -258.314% |
| Aptose Biosciences Inc. | 15.8 Million USD | -64.89% |
| NKGen Biotech, Inc. Common Stock | 75.17 Million USD | 65.324% |
| Century Therapeutics, Inc. | 175.94 Million USD | 85.184% |
| Eterna Therapeutics Inc. | 46.89 Million USD | 44.419% |
| Precision BioSciences, Inc. | 140.92 Million USD | 81.502% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 93.438% |
| Kura Oncology, Inc. | 51.66 Million USD | 49.543% |
| Xenetic Biosciences, Inc. | 809.58 Thousand USD | -3119.798% |
| Dyadic International, Inc. | 2.34 Million USD | -1013.665% |
| TScan Therapeutics, Inc. | 121.28 Million USD | 78.507% |
| IDEAYA Biosciences, Inc. | 28.22 Million USD | 7.649% |
| CytomX Therapeutics, Inc. | 252.59 Million USD | 89.68% |
| Autolus Therapeutics plc | 263.9 Million USD | 90.123% |
| Eton Pharmaceuticals, Inc. | 16.26 Million USD | -60.284% |
| EyePoint Pharmaceuticals, Inc. | 88.86 Million USD | 70.665% |
| GRI Bio, Inc. | 2.69 Million USD | -866.518% |
| Tenaya Therapeutics, Inc. | 31.09 Million USD | 16.159% |
| IGM Biosciences, Inc. | 220.17 Million USD | 88.161% |
| Heron Therapeutics, Inc. | 256.47 Million USD | 89.837% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | 2.158% |
| Entero Therapeutics, Inc. | 3.28 Million USD | -694.661% |
| Opthea Limited | 264.6 Million USD | 90.149% |
| X4 Pharmaceuticals, Inc. | 96.15 Million USD | 72.892% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 90.154% |
| Pliant Therapeutics, Inc. | 38.57 Million USD | 32.43% |
| Ligand Pharmaceuticals Incorporated | 130.7 Million USD | 80.057% |
| Surrozen, Inc. | 8.14 Million USD | -220.037% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -8205.348% |
| Cingulate Inc. | 10.36 Million USD | -151.591% |
| Ovid Therapeutics Inc. | 56.22 Million USD | 53.642% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 94.729% |
| Acelyrin, Inc. | 86.35 Million USD | 69.813% |
| Centessa Pharmaceuticals plc | 126.72 Million USD | 79.43% |
| Hepion Pharmaceuticals, Inc. | 10.81 Million USD | -141.058% |
| Arcturus Therapeutics Holdings Inc. | 150.88 Million USD | 82.724% |
| Syros Pharmaceuticals, Inc. | 151.51 Million USD | 82.795% |
| ADMA Biologics, Inc. | 193.97 Million USD | 86.562% |
| PureTech Health plc | 125.58 Million USD | 79.243% |
| Oncternal Therapeutics, Inc. | 6.67 Million USD | -290.4% |
| FibroBiologics, Inc. Common Stock | 10.56 Million USD | -146.66% |
| Barinthus Biotherapeutics plc | 27.51 Million USD | 5.249% |
| Kymera Therapeutics, Inc. | 180.78 Million USD | 85.581% |
| Synaptogenix, Inc. | 5.52 Million USD | -371.42% |
| Tiziana Life Sciences Ltd | 6.64 Million USD | -292.103% |
| ChromaDex Corporation | 26.5 Million USD | 1.664% |
| Inhibikase Therapeutics, Inc. | 3.52 Million USD | -638.709% |
| Monopar Therapeutics Inc. | 1.75 Million USD | -1383.277% |
| Exelixis, Inc. | 678.44 Million USD | 96.158% |
| Akebia Therapeutics, Inc. | 272.28 Million USD | 90.427% |
| Better Therapeutics, Inc. | 23.84 Million USD | -9.332% |
| Nurix Therapeutics, Inc. | 164.04 Million USD | 84.11% |
| Apellis Pharmaceuticals, Inc. | 594.2 Million USD | 95.613% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | 68.378% |
| Seer, Inc. | 39.36 Million USD | 33.781% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | 33.036% |
| LAVA Therapeutics N.V. | 50.53 Million USD | 48.415% |
| Gritstone bio, Inc. | 125.91 Million USD | 79.299% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -77.617% |
| Avid Bioservices, Inc. | 275.66 Million USD | 90.544% |
| Insmed Incorporated | 1.66 Billion USD | 98.431% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | -57.867% |
| Avalo Therapeutics, Inc. | 13.68 Million USD | -90.423% |
| Fate Therapeutics, Inc. | 137.8 Million USD | 81.083% |
| MediWound Ltd. | 27.18 Million USD | 4.12% |
| BioXcel Therapeutics, Inc. | 130.21 Million USD | 79.981% |
| Fortress Biotech, Inc. | 165.93 Million USD | 84.291% |
| OmniAb, Inc. | 87.4 Million USD | 70.175% |
| Seres Therapeutics, Inc. | 403.45 Million USD | 93.539% |
| Zai Lab Limited | 240.17 Million USD | 89.147% |
| Revance Therapeutics, Inc. | 630.05 Million USD | 95.863% |
| Tarsus Pharmaceuticals, Inc. | 69.23 Million USD | 62.351% |
| Veracyte, Inc. | 93.71 Million USD | 72.186% |
| Abeona Therapeutics Inc. | 49.17 Million USD | 46.992% |
| FibroGen, Inc. | 585.72 Million USD | 95.55% |
| Apogee Therapeutics, Inc. | 21.49 Million USD | -21.293% |
| ContextLogic Inc. | 206 Million USD | 87.346% |
| Intensity Therapeutics, Inc. | 4.13 Million USD | -530.704% |
| Adial Pharmaceuticals, Inc. | 653.07 Thousand USD | -3891.419% |
| HOOKIPA Pharma Inc. | 71.48 Million USD | 63.532% |
| Jazz Pharmaceuticals plc | 7.65 Billion USD | 99.66% |
| Entrada Therapeutics, Inc. | 226.83 Million USD | 88.508% |
| Cyclacel Pharmaceuticals, Inc. | 8.19 Million USD | -217.968% |
| ImmuCell Corporation | 18.81 Million USD | -38.544% |
| Fortrea Holdings Inc. | 2.61 Billion USD | 99.004% |
| KalVista Pharmaceuticals, Inc. | 28.82 Million USD | 9.559% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -77.617% |
| Foghorn Therapeutics Inc. | 363.1 Million USD | 92.821% |
| Ultragenyx Pharmaceutical Inc. | 1.21 Billion USD | 97.856% |
| Theravance Biopharma, Inc. | 169 Million USD | 84.576% |
| Metagenomi, Inc. Common Stock | 500.42 Million USD | 94.791% |
| Vaxxinity, Inc. | 30.94 Million USD | 15.761% |
| BioCryst Pharmaceuticals, Inc. | 972.48 Million USD | 97.32% |
| Gain Therapeutics, Inc. | 6.03 Million USD | -332.209% |
| Creative Medical Technology Holdings, Inc. | 371.39 Thousand USD | -6918.692% |
| Marker Therapeutics, Inc. | 3.07 Million USD | -747.749% |
| CASI Pharmaceuticals, Inc. | 51.1 Million USD | 48.991% |
| Senti Biosciences, Inc. | 52.57 Million USD | 50.416% |
| BioRestorative Therapies, Inc. | 2.6 Million USD | -899.753% |
| Apollomics, Inc. | 14.15 Million USD | -84.18% |
| 89bio, Inc. | 59.96 Million USD | 56.528% |
| Arrowhead Pharmaceuticals, Inc. | 478.39 Million USD | 94.551% |
| TransCode Therapeutics, Inc. | 3.52 Million USD | -638.675% |
| RAPT Therapeutics, Inc. | 26.29 Million USD | 0.863% |
| Ardelyx, Inc. | 130.76 Million USD | 80.065% |
| Pluri Inc. | 34.11 Million USD | 23.584% |
| Prothena Corporation plc | 135.01 Million USD | 80.694% |
| Pulmatrix, Inc. | 15.96 Million USD | -63.296% |
| Celularity Inc. | 102.92 Million USD | 74.675% |
| MeiraGTx Holdings plc | 319.99 Million USD | 91.854% |
| Omeros Corporation | 403.25 Million USD | 93.536% |
| Ainos, Inc. | 7.39 Million USD | -252.532% |
| Humacyte, Inc. | 114.67 Million USD | 77.269% |
| Mesoblast Limited | 188.79 Million USD | 86.193% |
| Cocrystal Pharma, Inc. | 4.87 Million USD | -434.708% |
| Cidara Therapeutics, Inc. | 76.74 Million USD | 66.032% |
| Blueprint Medicines Corporation | 918.64 Million USD | 97.162% |
| Cabaletta Bio, Inc. | 17.45 Million USD | -49.364% |
| Summit Therapeutics Inc. | 125.25 Million USD | 79.189% |
| Alaunos Therapeutics, Inc. | 1.95 Million USD | -1232.669% |
| Scholar Rock Holding Corporation | 85.81 Million USD | 69.625% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | 89.607% |
| Adlai Nortye Ltd. American Depositary Shares | 50.78 Million USD | 48.673% |
| Cytokinetics, Incorporated | 1.21 Billion USD | 97.847% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | 17.984% |
| Nutriband Inc. | 1.07 Million USD | -2316.029% |
| Protara Therapeutics, Inc. | 10.63 Million USD | -145.152% |
| Roivant Sciences Ltd. | 773.95 Million USD | 96.632% |
| Evogene Ltd. | 17.99 Million USD | -44.897% |
| Applied Therapeutics, Inc. | 71.97 Million USD | 63.785% |
| Hoth Therapeutics, Inc. | 704.98 Thousand USD | -3597.536% |
| BridgeBio Pharma, Inc. | 1.88 Billion USD | 98.62% |
| BioLineRx Ltd. | 50.7 Million USD | 48.588% |
| Atai Life Sciences N.V. | 49.16 Million USD | 46.977% |
| VistaGen Therapeutics, Inc. | 9.36 Million USD | -178.285% |
| Aurinia Pharmaceuticals Inc. | 170.1 Million USD | 84.676% |
| MediciNova, Inc. | 3.89 Million USD | -569.835% |
| Praxis Precision Medicines, Inc. | 18.27 Million USD | -42.606% |
| MiMedx Group, Inc. | 96.33 Million USD | 72.94% |
| PTC Therapeutics, Inc. | 2.72 Billion USD | 99.042% |
| Cullinan Oncology, Inc. | 31.2 Million USD | 16.455% |
| Syndax Pharmaceuticals, Inc. | 58.68 Million USD | 55.581% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -858.908% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -36.849% |
| 4D Molecular Therapeutics, Inc. | 32.06 Million USD | 18.698% |
| Dyne Therapeutics, Inc. | 73.79 Million USD | 64.674% |
| Kiniksa Pharmaceuticals, Ltd. | 87.48 Million USD | 70.203% |
| Ventyx Biosciences, Inc. | 33.77 Million USD | 22.81% |
| Allakos Inc. | 74.79 Million USD | 65.148% |
| Fulcrum Therapeutics, Inc. | 22.5 Million USD | -15.848% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | 77.296% |
| BioAtla, Inc. | 48.98 Million USD | 46.787% |
| Allogene Therapeutics, Inc. | 130.6 Million USD | 80.041% |
| Larimar Therapeutics, Inc. | 14.21 Million USD | -83.377% |
| Precigen, Inc. | 41.64 Million USD | 37.405% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -204.621% |
| XOMA Corporation | 145.58 Million USD | 82.094% |
| Kezar Life Sciences, Inc. | 33.66 Million USD | 22.569% |
| Incyte Corporation | 1.59 Billion USD | 98.363% |
| Cara Therapeutics, Inc. | 68.75 Million USD | 62.089% |
| Aligos Therapeutics, Inc. | 61.82 Million USD | 57.836% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -294.519% |
| CRISPR Therapeutics AG | 346.76 Million USD | 92.483% |
| Akero Therapeutics, Inc. | 44.96 Million USD | 42.028% |
| Eliem Therapeutics, Inc. | 2.87 Million USD | -808.258% |
| EyeGate Pharmaceuticals, Inc. | 8.15 Million USD | -219.526% |
| UroGen Pharma Ltd. | 243.52 Million USD | 89.296% |
| Sutro Biopharma, Inc. | 321.08 Million USD | 91.882% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -843.924% |
| Lisata Therapeutics, Inc. | 6.8 Million USD | -283.338% |
| Stoke Therapeutics, Inc. | 68.77 Million USD | 62.099% |
| Chimerix, Inc. | 19.74 Million USD | -32.018% |
| Outlook Therapeutics, Inc. | 46.73 Million USD | 44.229% |
| 60 Degrees Pharmaceuticals, Inc. | 2.98 Million USD | -773.069% |
| Enanta Pharmaceuticals, Inc. | 245.54 Million USD | 89.384% |
| Aprea Therapeutics, Inc. | 4.38 Million USD | -494.376% |
| Portage Biotech Inc. | 4.45 Million USD | -485.775% |
| OncoCyte Corporation | 49.29 Million USD | 47.124% |
| Qualigen Therapeutics, Inc. | 4.13 Million USD | -530.124% |
| Cadrenal Therapeutics, Inc. Common Stock | 826.87 Thousand USD | -3052.472% |
| Processa Pharmaceuticals, Inc. | 797.48 Thousand USD | -3168.655% |
| Purple Biotech Ltd. | 10 Million USD | -160.54% |
| NextCure, Inc. | 14.99 Million USD | -73.815% |
| ProMIS Neurosciences, Inc. | 12.38 Million USD | -110.421% |
| Dermata Therapeutics, Inc. | 1.62 Million USD | -1505.49% |
| Generation Bio Co. | 171.63 Million USD | 84.812% |
| Neumora Therapeutics, Inc. Common Stock | 27.11 Million USD | 3.879% |
| Xeris Biopharma Holdings, Inc. | 347.58 Million USD | 92.5% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -138.84% |
| NLS Pharmaceutics AG | 10.68 Million USD | -144.068% |
| Mineralys Therapeutics, Inc. | 10.48 Million USD | -148.683% |
| Novavax, Inc. | 2.57 Billion USD | 98.987% |
| Virios Therapeutics, Inc. | 358.54 Thousand USD | -7170.156% |
| Curis, Inc. | 57.61 Million USD | 54.754% |
| Daré Bioscience, Inc. | 26.32 Million USD | 0.998% |
| Titan Pharmaceuticals, Inc. | 1.44 Million USD | -1705.194% |
| Virpax Pharmaceuticals, Inc. | 7.69 Million USD | -238.795% |
| Bicycle Therapeutics plc | 224.41 Million USD | 88.384% |
| BeiGene, Ltd. | 2.23 Billion USD | 98.833% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | -22.439% |
| Alector, Inc. | 487.66 Million USD | 94.655% |
| Protagonist Therapeutics, Inc. | 21.27 Million USD | -22.53% |
| Erasca, Inc. | 78.61 Million USD | 66.841% |
| Checkpoint Therapeutics, Inc. | 18.42 Million USD | -41.476% |
| Aura Biosciences, Inc. | 29.22 Million USD | 10.812% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | 32.069% |
| Chemomab Therapeutics Ltd. | 5.15 Million USD | -405.76% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -3878.164% |
| Pieris Pharmaceuticals, Inc. | 11.92 Million USD | -118.646% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 98.621% |
| Histogen Inc. | 5.69 Million USD | -357.557% |
| Fortress Biotech, Inc. | 165.93 Million USD | 84.291% |
| Avidity Biosciences, Inc. | 127.79 Million USD | 79.602% |
| Lyell Immunopharma, Inc. | 95.07 Million USD | 72.583% |
| Galecto, Inc. | 5.89 Million USD | -342.113% |
| InMed Pharmaceuticals Inc. | 2.61 Million USD | -896.189% |
| Phathom Pharmaceuticals, Inc. | 486.6 Million USD | 94.643% |
| Molecular Templates, Inc. | 31.17 Million USD | 16.374% |
| PDS Biotechnology Corporation | 33.25 Million USD | 21.625% |
| Amylyx Pharmaceuticals, Inc. | 84.02 Million USD | 68.976% |
| Amarin Corporation plc | 279.58 Million USD | 90.677% |
| TG Therapeutics, Inc. | 169.08 Million USD | 84.583% |
| Aptevo Therapeutics Inc. | 12.62 Million USD | -106.537% |
| Celldex Therapeutics, Inc. | 36.45 Million USD | 28.497% |
| Cogent Biosciences, Inc. | 55.63 Million USD | 53.146% |
| Onconetix, Inc. | 23.18 Million USD | -12.45% |
| MacroGenics, Inc. | 154.2 Million USD | 83.096% |
| Y-mAbs Therapeutics, Inc. | 26.88 Million USD | 3.039% |
| Ocuphire Pharma, Inc. | 4.04 Million USD | -544.904% |
| Adagene Inc. | 45.16 Million USD | 42.291% |
| Inhibrx Biosciences, Inc. | 264.39 Million USD | 90.141% |
| Cartesian Therapeutics, Inc. | 745.23 Million USD | 96.502% |
| Voyager Therapeutics, Inc. | 114.96 Million USD | 77.325% |
| SciSparc Ltd. | 1.59 Million USD | -1534.295% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -368.419% |
| Minerva Neurosciences, Inc. | 85.35 Million USD | 69.462% |
| Astria Therapeutics, Inc. | 11.55 Million USD | -125.688% |
| Black Diamond Therapeutics, Inc. | 41.83 Million USD | 37.685% |
| Arcutis Biotherapeutics, Inc. | 252.69 Million USD | 89.685% |
| Relay Therapeutics, Inc. | 91.97 Million USD | 71.659% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 99.356% |
| Psyence Biomedical Ltd. | 12.1 Million USD | -115.346% |
| Artelo Biosciences, Inc. | 1.02 Million USD | -2453.085% |
| 2seventy bio, Inc. | 310.12 Million USD | 91.595% |
| Clene Inc. | 38.95 Million USD | 33.077% |
| Boundless Bio, Inc. Common Stock | 256.97 Million USD | 89.856% |
| GeoVax Labs, Inc. | 3.51 Million USD | -640.565% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.65 Million USD | -360.918% |
| Arbutus Biopharma Corporation | 38.38 Million USD | 32.087% |
| Scopus BioPharma Inc. | 7.45 Million USD | -249.684% |
| Absci Corporation | 58.3 Million USD | 55.291% |
| XBiotech Inc. | 8.39 Million USD | -210.432% |
| ALX Oncology Holdings Inc. | 52.84 Million USD | 50.669% |
| Lyra Therapeutics, Inc. | 53.18 Million USD | 50.983% |
| Entera Bio Ltd. | 1.37 Million USD | -1790.283% |
| Trevena, Inc. | 48.26 Million USD | 45.989% |
| Adaptimmune Therapeutics plc | 243.1 Million USD | 89.277% |
| Caribou Biosciences, Inc. | 72.56 Million USD | 64.079% |
| INmune Bio, Inc. | 18.86 Million USD | -38.198% |
| Citius Pharmaceuticals, Inc. | 12.17 Million USD | -114.021% |
| Tyra Biosciences, Inc. | 21.59 Million USD | -20.708% |
| Galmed Pharmaceuticals Ltd. | 2.75 Million USD | -847.891% |
| Unity Biotechnology, Inc. | 37.29 Million USD | 30.1% |
| Tenax Therapeutics, Inc. | 3.58 Million USD | -626.805% |
| Jaguar Health, Inc. | 45.86 Million USD | 43.167% |
| Clearside Biomedical, Inc. | 49.93 Million USD | 47.793% |
| NexImmune, Inc. | 5.08 Million USD | -412.703% |
| Connect Biopharma Holdings Limited | 24.84 Million USD | -4.902% |
| Clearmind Medicine Inc. | 3.61 Million USD | -622.076% |
| Coeptis Therapeutics Holdings, Inc. | 3.75 Million USD | -593.802% |
| Kronos Bio, Inc. | 54.2 Million USD | 51.907% |
| Innoviva, Inc. | 568.55 Million USD | 95.415% |
| Coherus BioSciences, Inc. | 823.02 Million USD | 96.833% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 99.633% |
| Bolt Biotherapeutics, Inc. | 47.04 Million USD | 44.589% |
| Verastem, Inc. | 71.18 Million USD | 63.381% |
| ProKidney Corp. | 29.21 Million USD | 10.778% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -14.531% |
| Imunon, Inc. | 8.53 Million USD | -205.577% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -29.874% |
| Statera Biopharma, Inc. | 22.67 Million USD | -14.952% |
| ImmunityBio, Inc. | 1.09 Billion USD | 97.609% |
| Korro Bio, Inc. | 51.75 Million USD | 49.631% |
| Travere Therapeutics, Inc. | 588.1 Million USD | 95.568% |
| Kineta, Inc. | 7.22 Million USD | -260.939% |
| Catalyst Pharmaceuticals, Inc. | 84.02 Million USD | 68.977% |
| Capricor Therapeutics, Inc. | 36.13 Million USD | 27.858% |
| GT Biopharma, Inc. | 6.63 Million USD | -292.99% |
| Keros Therapeutics, Inc. | 37.81 Million USD | 31.062% |
| Celularity Inc. | 102.92 Million USD | 74.675% |
| Crinetics Pharmaceuticals, Inc. | 96.24 Million USD | 72.917% |
| CalciMedica, Inc. | 4.02 Million USD | -547.145% |
| Cibus, Inc. | 206.11 Million USD | 87.353% |
| C4 Therapeutics, Inc. | 130.33 Million USD | 80.0% |
| Marinus Pharmaceuticals, Inc. | 154.14 Million USD | 83.089% |
| Eledon Pharmaceuticals, Inc. | 42.47 Million USD | 38.63% |
| Kodiak Sciences Inc. | 213.59 Million USD | 87.796% |
| Sana Biotechnology, Inc. | 277.79 Million USD | 90.616% |
| Annexon, Inc. | 47.11 Million USD | 44.677% |
| Adverum Biotechnologies, Inc. | 89.54 Million USD | 70.888% |
| Assembly Biosciences, Inc. | 96.37 Million USD | 72.952% |
| Elicio Therapeutics, Inc. | 15.77 Million USD | -65.263% |
| Moderna, Inc. | 4.57 Billion USD | 99.43% |
| Vigil Neuroscience, Inc. | 24.6 Million USD | -5.938% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 98.999% |
| Vor Biopharma Inc. | 59.1 Million USD | 55.896% |
| Eyenovia, Inc. | 19.78 Million USD | -31.783% |
| DiaMedica Therapeutics Inc. | 3.1 Million USD | -740.058% |
| Puma Biotechnology, Inc. | 177.08 Million USD | 85.28% |
| Monte Rosa Therapeutics, Inc. | 124.5 Million USD | 79.063% |
| Wave Life Sciences Ltd. | 227.44 Million USD | 88.539% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -239.37% |
| ACADIA Pharmaceuticals Inc. | 317.2 Million USD | 91.782% |
| Immunocore Holdings plc | 228.15 Million USD | 88.575% |
| Tango Therapeutics, Inc. | 149.45 Million USD | 82.559% |
| Galectin Therapeutics Inc. | 88.44 Million USD | 70.526% |
| Alkermes plc | 933.53 Million USD | 97.208% |
| Arcellx, Inc. | 339.75 Million USD | 92.328% |
| Renovaro Biosciences Inc. | 31.15 Million USD | 16.324% |
| Zentalis Pharmaceuticals, Inc. | 124.63 Million USD | 79.085% |
| Sagimet Biosciences Inc. | 5.65 Million USD | -361.036% |
| Regulus Therapeutics Inc. | 9.56 Million USD | -172.582% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -1632.901% |
| Moolec Science SA | 13.94 Million USD | -86.922% |
| Biomea Fusion, Inc. | 30.69 Million USD | 15.064% |
| RenovoRx, Inc. | 4.46 Million USD | -483.677% |
| Geron Corporation | 146.12 Million USD | 82.161% |
| Mereo BioPharma Group plc | 15.96 Million USD | -63.307% |
| Verrica Pharmaceuticals Inc. | 61.83 Million USD | 57.844% |
| Royalty Pharma plc | 6.29 Billion USD | 99.586% |
| Atea Pharmaceuticals, Inc. | 39.77 Million USD | 34.466% |
| Greenwich LifeSciences, Inc. | 294.4 Thousand USD | -8754.099% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -214.667% |
| TFF Pharmaceuticals, Inc. | 2.46 Million USD | -959.513% |
| Mersana Therapeutics, Inc. | 189.15 Million USD | 86.219% |
| Humacyte, Inc. | 114.67 Million USD | 77.269% |
| Structure Therapeutics Inc. | 29.05 Million USD | 10.272% |
| NLS Pharmaceutics AG | 10.68 Million USD | -144.068% |
| Genelux Corporation | 8.42 Million USD | -209.584% |
| ESSA Pharma Inc. | 3.49 Million USD | -645.822% |
| aTyr Pharma, Inc. | 31.59 Million USD | 17.502% |
| Notable Labs, Ltd. | 4.42 Million USD | -488.819% |
| Alzamend Neuro, Inc. | 3.22 Million USD | -708.085% |
| Mustang Bio, Inc. | 17.61 Million USD | -47.948% |
| Immunovant, Inc. | 48.95 Million USD | 46.753% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -46.996% |
| Vericel Corporation | 127.7 Million USD | 79.588% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 98.42% |
| Akari Therapeutics, Plc | 4.58 Million USD | -468.652% |
| Acasti Pharma Inc. | 11.55 Million USD | -125.552% |
| MiNK Therapeutics, Inc. | 22.6 Million USD | -15.301% |
| Vaxcyte, Inc. | 167.44 Million USD | 84.433% |
| Orgenesis Inc. | 35.53 Million USD | 26.644% |
| Spruce Biosciences, Inc. | 27.43 Million USD | 4.993% |
| NeuroBo Pharmaceuticals, Inc. | 6.09 Million USD | -327.608% |
| GH Research PLC | 6.7 Million USD | -289.002% |
| Tempest Therapeutics, Inc. | 24.83 Million USD | -4.961% |
| PepGen Inc. | 34.63 Million USD | 24.729% |
| Moleculin Biotech, Inc. | 12.14 Million USD | -114.649% |
| Relmada Therapeutics, Inc. | 12.19 Million USD | -113.755% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -204.621% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -8205.348% |
| Silo Pharma, Inc. | 1.56 Million USD | -1561.091% |
| Telomir Pharmaceuticals, Inc. Common Stock | 1.33 Million USD | -1851.76% |
| Belite Bio, Inc | 4.21 Million USD | -519.022% |
| Pharming Group N.V. | 244.07 Million USD | 89.32% |
| XOMA Corporation | 145.58 Million USD | 82.094% |
| Reneo Pharmaceuticals, Inc. | 18.82 Million USD | -38.463% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -294.519% |
| Bionomics Limited | 10.15 Million USD | -156.597% |
| Xencor, Inc. | 283.55 Million USD | 90.807% |
| Replimune Group, Inc. | 113.21 Million USD | 76.975% |
| Pyxis Oncology, Inc. | 48.02 Million USD | 45.719% |
| Cassava Sciences, Inc. | 14.19 Million USD | -83.635% |
| Vanda Pharmaceuticals Inc. | 103.53 Million USD | 74.822% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -14325.487% |
| Turnstone Biologics Corp. | 14.14 Million USD | -84.245% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 10.16% |
| GeoVax Labs, Inc. | 3.51 Million USD | -640.565% |
| MEI Pharma, Inc. | 8.35 Million USD | -211.993% |
| Olema Pharmaceuticals, Inc. | 23.05 Million USD | -13.089% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -1632.901% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -837.999% |
| Enlivex Therapeutics Ltd. | 6.74 Million USD | -286.349% |
| CollPlant Biotechnologies Ltd. | 5.78 Million USD | -350.518% |
| scPharmaceuticals Inc. | 57.26 Million USD | 54.477% |
| HilleVax, Inc. | 78.9 Million USD | 66.966% |
| Vera Therapeutics, Inc. | 73.86 Million USD | 64.708% |
| Tharimmune, Inc. | 1.81 Million USD | -1336.162% |
| Genprex, Inc. | 3.25 Million USD | -701.024% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -49.957% |
| Immunic, Inc. | 25.36 Million USD | -2.755% |
| Atossa Therapeutics, Inc. | 5.23 Million USD | -397.842% |
| Aptorum Group Limited | 5.25 Million USD | -395.878% |
| Soleno Therapeutics, Inc. | 23.18 Million USD | -12.435% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -49.957% |
| OKYO Pharma Limited | 7.42 Million USD | -251.267% |
| Carmell Therapeutics Corporation | 39.19 Million USD | 33.502% |
| Achieve Life Sciences, Inc. | 20.81 Million USD | -25.208% |
| Ocean Biomedical, Inc. | 6.61 Million USD | -294.127% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 95.78% |
| Salarius Pharmaceuticals, Inc. | 1.29 Million USD | -1906.325% |
| bluebird bio, Inc. | 424.62 Million USD | 93.861% |
| DBV Technologies S.A. | 42.8 Million USD | 39.096% |
| Compugen Ltd. | 55.77 Million USD | 53.264% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -3878.164% |
| Peak Bio, Inc. | 20.75 Million USD | -25.604% |
| Vincerx Pharma, Inc. | 6.99 Million USD | -272.652% |
| Fresh Tracks Therapeutics, Inc. | 1.65 Million USD | -1474.094% |
| Sensei Biotherapeutics, Inc. | 9.47 Million USD | -174.997% |
| Orchestra BioMed Holdings, Inc. | 27.16 Million USD | 4.056% |
| Zevra Therapeutics, Inc. | 110.46 Million USD | 76.402% |
| Acrivon Therapeutics, Inc. Common Stock | 17.07 Million USD | -52.707% |
| Benitec Biopharma Inc. | 4.96 Million USD | -425.333% |
| Spyre Therapeutics, Inc. | 157.84 Million USD | 83.485% |
| Adicet Bio, Inc. | 37.12 Million USD | 29.776% |
| Prime Medicine, Inc. | 60.78 Million USD | 57.113% |
| Aditxt, Inc. | 28.53 Million USD | 8.638% |
| Madrigal Pharmaceuticals, Inc. | 235.21 Million USD | 88.918% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -14325.487% |
| Quantum-Si incorporated | 26.63 Million USD | 2.118% |
| GlycoMimetics, Inc. | 6.9 Million USD | -277.669% |
| PolyPid Ltd. | 17.46 Million USD | -49.227% |
| Aileron Therapeutics, Inc. | 112.39 Million USD | 76.809% |
| Invivyd, Inc. | 51.71 Million USD | 49.593% |
| Quoin Pharmaceuticals, Ltd. | 6.5 Million USD | -300.707% |
| Rigel Pharmaceuticals, Inc. | 145.86 Million USD | 82.13% |
| CorMedix Inc. | 11.91 Million USD | -118.728% |
| Instil Bio, Inc. | 99.8 Million USD | 73.881% |
| Recursion Pharmaceuticals, Inc. | 190.26 Million USD | 86.299% |
| Contineum Therapeutics, Inc. Class A Common Stock | 198.32 Million USD | 86.856% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | 45.819% |
| Spero Therapeutics, Inc. | 75.49 Million USD | 65.472% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -13.765% |
| AbCellera Biologics Inc. | 335.77 Million USD | 92.237% |
| Ocular Therapeutix, Inc. | 160.92 Million USD | 83.802% |
| Surrozen, Inc. | 8.14 Million USD | -220.037% |
| Janux Therapeutics, Inc. | 36.05 Million USD | 27.708% |
| Verona Pharma plc | 58.84 Million USD | 55.699% |
| Terns Pharmaceuticals, Inc. | 13.15 Million USD | -98.228% |
| Vir Biotechnology, Inc. | 369.85 Million USD | 92.952% |
| Evaxion Biotech A/S | 17.61 Million USD | -47.961% |
| Verve Therapeutics, Inc. | 153.18 Million USD | 82.983% |
| Shattuck Labs, Inc. | 14.85 Million USD | -75.429% |
| AlloVir, Inc. | 45.01 Million USD | 42.093% |
| BioVie Inc. | 9.7 Million USD | -168.673% |
| Codexis, Inc. | 49.94 Million USD | 47.81% |
| SELLAS Life Sciences Group, Inc. | 14.37 Million USD | -81.285% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -6353.697% |
| Agenus Inc. | 462.29 Million USD | 94.361% |
| Virax Biolabs Group Limited | 345.19 Thousand USD | -7451.406% |
| Lantern Pharma Inc. | 2.73 Million USD | -851.461% |
| Viridian Therapeutics, Inc. | 48.4 Million USD | 46.145% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | 1.033% |
| Immix Biopharma, Inc. | 3.72 Million USD | -600.39% |
| Celcuity Inc. | 51.45 Million USD | 49.335% |
| Cardiff Oncology, Inc. | 11.89 Million USD | -119.087% |
| Acumen Pharmaceuticals, Inc. | 43.15 Million USD | 39.593% |
| IN8bio, Inc. | 8.77 Million USD | -197.161% |
| Avenue Therapeutics, Inc. | 1.19 Million USD | -2079.515% |
| Trevi Therapeutics, Inc. | 6.85 Million USD | -280.207% |
| Lexicon Pharmaceuticals, Inc. | 136.31 Million USD | 80.878% |
| Liquidia Corporation | 73.13 Million USD | 64.359% |
| Quantum-Si incorporated | 26.63 Million USD | 2.118% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -858.908% |
| Xenon Pharmaceuticals Inc. | 36.87 Million USD | 29.314% |
| Sol-Gel Technologies Ltd. | 6.64 Million USD | -292.398% |
| United Therapeutics Corporation | 1.18 Billion USD | 97.795% |
| Solid Biosciences Inc. | 38.45 Million USD | 32.22% |
| Immuneering Corporation | 12 Million USD | -117.074% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -13.765% |
| uniQure N.V. | 624.01 Million USD | 95.823% |
| Xilio Therapeutics, Inc. | 24.09 Million USD | -8.166% |
| Enveric Biosciences, Inc. | 2.34 Million USD | -1012.309% |
| Poseida Therapeutics, Inc. | 170.18 Million USD | 84.683% |
| Longboard Pharmaceuticals, Inc. | 9.77 Million USD | -166.697% |
| PMV Pharmaceuticals, Inc. | 26.46 Million USD | 1.496% |
| Elevai Labs, Inc. Common Stock | 1.36 Million USD | -1812.694% |
| Cue Biopharma, Inc. | 24.44 Million USD | -6.635% |
| Nuvectis Pharma, Inc. | 6.98 Million USD | -273.239% |
| ARS Pharmaceuticals, Inc. | 2.42 Million USD | -973.6% |
| Zura Bio Limited | 21.29 Million USD | -22.426% |
| Forte Biosciences, Inc. | 3.66 Million USD | -611.047% |
| Elevation Oncology, Inc. | 34.28 Million USD | 23.963% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -239.37% |
| Immunome, Inc. | 28.65 Million USD | 9.041% |
| Compass Therapeutics, Inc. | 8.33 Million USD | -212.666% |
| enGene Holdings Inc. Warrants | 14.47 Million USD | -80.108% |
| Inovio Pharmaceuticals, Inc. | 55.59 Million USD | 53.113% |
| LENZ Therapeutics, Inc. | 4.87 Million USD | -434.817% |
| Altimmune, Inc. | 16.54 Million USD | -57.59% |
| Milestone Pharmaceuticals Inc. | 58.45 Million USD | 55.407% |
| Rallybio Corporation | 9.43 Million USD | -176.251% |
| Plus Therapeutics, Inc. | 12.73 Million USD | -104.672% |
| Dianthus Therapeutics, Inc. | 10.53 Million USD | -147.432% |
| Moolec Science SA | 13.94 Million USD | -86.922% |
| Anebulo Pharmaceuticals, Inc. | 260.58 Thousand USD | -9903.339% |
| XTL Biopharmaceuticals Ltd. | 206 Thousand USD | -12553.883% |
| Tourmaline Bio, Inc. | 5.25 Million USD | -396.231% |
| NeurAxis, Inc. | 1.91 Million USD | -1262.81% |
| Maravai LifeSciences Holdings, Inc. | 697.56 Million USD | 96.263% |
| Lumos Pharma, Inc. | 13.33 Million USD | -95.507% |
| enGene Holdings Inc. Common Stock | 14.47 Million USD | -80.108% |
| 180 Life Sciences Corp. | 5.38 Million USD | -383.868% |
| NKGen Biotech, Inc. Warrants | 75.17 Million USD | 65.324% |
| Opiant Pharmaceuticals, Inc. | 23.58 Million USD | -10.51% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -14.531% |
| Nutriband Inc. | 1.07 Million USD | -2316.029% |
| CG Oncology, Inc. Common stock | 14.51 Million USD | -79.636% |
| argenx SE | 444.95 Million USD | 94.142% |
| Neurogene Inc. | 36.54 Million USD | 28.679% |
| Mirum Pharmaceuticals, Inc. | 397.95 Million USD | 93.45% |
| Kintara Therapeutics, Inc. | 2.44 Million USD | -966.135% |
| CervoMed Inc. | 2.59 Million USD | -904.22% |
| CARGO Therapeutics, Inc. Common Stock | 47.65 Million USD | 45.295% |
| Sesen Bio, Inc. | 30.98 Million USD | 15.869% |
| AnaptysBio, Inc. | 364.28 Million USD | 92.844% |
| Design Therapeutics, Inc. | 11.95 Million USD | -118.024% |
| Leap Therapeutics, Inc. | 12.68 Million USD | -105.511% |
| Seelos Therapeutics, Inc. | 38.92 Million USD | 33.038% |
| Achilles Therapeutics plc | 19.08 Million USD | -36.569% |
| NeuroSense Therapeutics Ltd. | 5.05 Million USD | -416.178% |
| ORIC Pharmaceuticals, Inc. | 30.59 Million USD | 14.808% |
| Fractyl Health, Inc. Common Stock | 401.27 Million USD | 93.504% |
| Rani Therapeutics Holdings, Inc. | 32.47 Million USD | 19.727% |
| MoonLake Immunotherapeutics | 13.04 Million USD | -99.761% |
| Palisade Bio, Inc. | 2.73 Million USD | -851.698% |
| Beam Therapeutics Inc. | 478.38 Million USD | 94.551% |
| AEON Biopharma, Inc. | 159.88 Million USD | 83.697% |
| Enliven Therapeutics, Inc. | 25.96 Million USD | -0.408% |
| Kiora Pharmaceuticals, Inc. | 7.6 Million USD | -242.887% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | 86.683% |
| Taysha Gene Therapies, Inc. | 192.05 Million USD | 86.427% |
| Athira Pharma, Inc. | 30.05 Million USD | 13.275% |
| Vaccinex, Inc. | 5.94 Million USD | -338.691% |
| HCW Biologics Inc. | 15.05 Million USD | -73.18% |
| XOMA Corporation | 145.58 Million USD | 82.094% |
| Nektar Therapeutics | 267.04 Million USD | 90.239% |
| Arvinas, Inc. | 644.6 Million USD | 95.956% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -46.996% |
| Merus N.V. | 102.15 Million USD | 74.482% |
| Omega Therapeutics, Inc. | 146.35 Million USD | 82.189% |
| Quince Therapeutics, Inc. | 95.12 Million USD | 72.596% |
| Rezolute, Inc. | 11.73 Million USD | -122.149% |
| Clene Inc. | 38.95 Million USD | 33.077% |
| Indaptus Therapeutics, Inc. | 2.84 Million USD | -815.473% |
| BeyondSpring Inc. | 48.26 Million USD | 45.996% |
| Synlogic, Inc. | 32.89 Million USD | 20.757% |
| Allarity Therapeutics, Inc. | 14.61 Million USD | -78.382% |
| Phio Pharmaceuticals Corp. | 1.63 Million USD | -1495.288% |
| Peak Bio, Inc. | 20.75 Million USD | -25.604% |
| Werewolf Therapeutics, Inc. | 63.45 Million USD | 58.923% |
| Krystal Biotech, Inc. | 39.71 Million USD | 34.363% |
| Karyopharm Therapeutics Inc. | 376.64 Million USD | 93.079% |
| SpringWorks Therapeutics, Inc. | 99.56 Million USD | 73.82% |
| Lipella Pharmaceuticals Inc. | 432.72 Thousand USD | -5923.904% |
| MannKind Corporation | 721.36 Million USD | 96.386% |
| Ikena Oncology, Inc. | 22.33 Million USD | -16.709% |
| Cyclerion Therapeutics, Inc. | 2.08 Million USD | -1149.616% |
| Gyre Therapeutics, Inc. | 102.59 Million USD | 74.591% |
| Gossamer Bio, Inc. | 249.14 Million USD | 89.538% |
| CohBar, Inc. | 1.03 Million USD | -2421.869% |
| Cognition Therapeutics, Inc. | 10.68 Million USD | -143.868% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -36.849% |
| Legend Biotech Corporation | 589.93 Million USD | 95.581% |
| Mural Oncology plc | 37.92 Million USD | 31.272% |
| Biora Therapeutics, Inc. | 132.63 Million USD | 80.347% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -1035.653% |
| Disc Medicine, Inc. | 22.87 Million USD | -13.954% |
| Champions Oncology, Inc. | 28.03 Million USD | 7.02% |
| REGENXBIO Inc. | 262.22 Million USD | 90.059% |
| Ensysce Biosciences, Inc. | 3.35 Million USD | -675.953% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -107.97% |
| Cellectar Biosciences, Inc. | 13.43 Million USD | -94.072% |
| Edgewise Therapeutics, Inc. | 21.2 Million USD | -22.929% |
| Vaxart, Inc. | 34.02 Million USD | 23.389% |
| PharmaCyte Biotech, Inc. | 20.38 Million USD | -27.847% |
| Aldeyra Therapeutics, Inc. | 28.53 Million USD | 8.639% |
| Cellectis S.A. | 249.57 Million USD | 89.555% |
| Longeveron Inc. | 5.33 Million USD | -388.42% |
| Repare Therapeutics Inc. | 41.81 Million USD | 37.667% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 98.916% |
| Inozyme Pharma, Inc. | 60.36 Million USD | 56.82% |
| Revolution Medicines, Inc. | 262.39 Million USD | 90.066% |
| Nymox Pharmaceutical Corporation | 2.1 Million USD | -1137.162% |
| Third Harmonic Bio, Inc. | 8.62 Million USD | -202.191% |
| ArriVent BioPharma, Inc. Common Stock | 11.8 Million USD | -120.888% |
| AN2 Therapeutics, Inc. | 14.04 Million USD | -85.623% |
| Anixa Biosciences, Inc. | 2.15 Million USD | -1111.855% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 99.494% |
| Denali Therapeutics Inc. | 122.96 Million USD | 78.801% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -368.419% |
| Veru Inc. | 32.81 Million USD | 20.558% |
| Corvus Pharmaceuticals, Inc. | 6.86 Million USD | -279.488% |
| Cingulate Inc. | 10.36 Million USD | -151.591% |
| Passage Bio, Inc. | 39.26 Million USD | 33.608% |
| Context Therapeutics Inc. | 4.19 Million USD | -521.87% |
| Exicure, Inc. | 8.54 Million USD | -204.913% |
| Day One Biopharmaceuticals, Inc. | 29.5 Million USD | 11.661% |
| Oramed Pharmaceuticals Inc. | 10.48 Million USD | -148.589% |
| Revolution Medicines, Inc. Warrant | 262.39 Million USD | 90.066% |
| Scinai Immunotherapeutics Ltd. | 22.04 Million USD | -18.266% |
| Rhythm Pharmaceuticals, Inc. | 162.98 Million USD | 84.007% |
| Nuvalent, Inc. | 31.82 Million USD | 18.088% |
| ABVC BioPharma, Inc. | 6.36 Million USD | -309.754% |
| Carisma Therapeutics, Inc. | 63.02 Million USD | 58.638% |
| Unicycive Therapeutics, Inc. | 18 Million USD | -44.817% |
| OmniAb, Inc. | 87.4 Million USD | 70.175% |
| Anew Medical, Inc. | 8.24 Million USD | -216.278% |
| Fennec Pharmaceuticals Inc. | 38.28 Million USD | 31.921% |
| Lipocine Inc. | 2.63 Million USD | -890.527% |
| Lexeo Therapeutics, Inc. Common Stock | 26.27 Million USD | 0.78% |
| Nautilus Biotechnology, Inc. | 40.21 Million USD | 35.176% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | 2.158% |
| G1 Therapeutics, Inc. | 86.15 Million USD | 69.744% |
| Bellerophon Therapeutics, Inc. | 5.4 Million USD | -382.633% |
| Sage Therapeutics, Inc. | 82.74 Million USD | 68.498% |
| Ocugen, Inc. | 23.98 Million USD | -8.689% |
| Mind Medicine (MindMed) Inc. | 46.4 Million USD | 43.83% |
| Q32 Bio Inc. | 233.12 Million USD | 88.819% |
| Brainstorm Cell Therapeutics Inc. | 9.06 Million USD | -187.525% |
| Alumis Inc. Common Stock | 53.5 Million USD | 51.278% |
| Equillium, Inc. | 27.95 Million USD | 6.76% |
| Kyverna Therapeutics, Inc. | 206.59 Million USD | 87.382% |
| Coya Therapeutics, Inc. | 5.62 Million USD | -363.276% |
| CNS Pharmaceuticals, Inc. | 6.13 Million USD | -325.031% |
| Galera Therapeutics, Inc. | 157.32 Million USD | 83.431% |
| Evelo Biosciences, Inc. | 69.43 Million USD | 62.457% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -161.344% |
| Dominari Holdings Inc. | 4.63 Million USD | -462.395% |
| Edesa Biotech, Inc. | 1.84 Million USD | -1315.426% |
| vTv Therapeutics Inc. | 29.56 Million USD | 11.838% |
| Bio-Techne Corporation | 744.34 Million USD | 96.498% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | 79.328% |
| Harmony Biosciences Holdings, Inc. | 344.45 Million USD | 92.432% |
| Prelude Therapeutics Incorporated | 40.57 Million USD | 35.756% |
| Candel Therapeutics, Inc. | 28.95 Million USD | 9.98% |
| iTeos Therapeutics, Inc. | 92.36 Million USD | 71.777% |
| Nkarta, Inc. | 105.6 Million USD | 75.315% |
| BioCardia, Inc. | 4.59 Million USD | -467.908% |
| Iterum Therapeutics plc | 32.66 Million USD | 20.192% |